Pfizer plans job cuts in Switzerland to reduce expenses

Group 1 - Pfizer plans to reduce its workforce in Switzerland from approximately 300 to 70 as part of a multi-year cost-cutting initiative [1] - The company is pursuing a cost-reduction plan exceeding $7 billion by 2027 to restore growth post-pandemic [2] - The job cuts in Switzerland are part of a broader trend in the pharmaceutical industry, with Novartis also announcing job eliminations [4] Group 2 - Pfizer is expanding its activities in the obesity treatment sector through a licensing deal worth up to $2 billion with YaoPharma [3] - The company recently won a bidding war against Novo Nordisk to acquire Metsera for $10 billion, indicating a strategic focus on obesity biotech [4]